Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of REGN2477 in Healthy Women
NCT02870400Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- Jan 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing REGN2477 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Jul 2016; status: completed.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT02870400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02870400.